Dr. Chung-Han Lee discusses ongoing pembrolizumab/lenvatinib trial in non-clear cell RCC

Small index lesions on initial multiparametric MRI were linked to a less aggressive clinical course for patients with prostate cancer on active surveillance.

Gopal H. Badlani, MD, and Steven A. Kaplan, MD, discuss some of the notable abstracts in benign urology that were presented at the 2023 AUA Annual Meeting.

The investigators reported that “the risk of recurrence was significantly lower following BLC (HR=0.67, 95% CI: 0.51-0.89) than WLC.”

Adam B. Weiner, MD, and Ruchika Talwar, MD, discuss some of the notable urologic oncology abstracts that were presented at the 2023 AUA meeting.

Primary chemoablative therapy with the mitomycin-containing reverse thermal gel UGN-102 induced complete responses in nearly 4 out of 5 patients with low-grade intermediate-risk non–muscle-invasive bladder cancer.

The oncolytic immunotherapy cretostimogene grenadenorepvec induced complete responses in over three-fourths of patients with high-risk BCG-unresponsive non–muscle-invasive bladder cancer.